Accedi a banche dati online | Convegnodetail
mail
Anteprima di stampa
 
 

6th Gene Therapy for Rare Disorders 2023

Evvnt Promotion / evvnt
-
20.03.2023 - 23.03.2023  Sheraton Boston Hotel, 39 Dalton St, 02199 Boston, USA
Time: 8:00 am to 5:00 pm
 
Temi della conferenza
2022 has been a landmark year for the global gene therapy space. With August came the green light for bluebird bio's Zynteglo in the US, the first FDA approval for a gene therapy in over three years. Hot off its heels we saw the accelerated approval of another bluebird bio product, Skysona. Overseas, July and August brought EMA approvals for PTC Therapeutics' Upstaza and BioMarin's Roctavian, the first gene therapies for AADC deficiency and Haemophilia A respectively.
Scientific organizer
Hanson Wade
Annotazioni
Speakers: Faraz Ali, Chief Executive Officer, Tenaya Therapeutics, Deborah Ascheim, Chief Medical Officer, Stridebio, Eduard Ayuso, Chief Executive and Technology Officer, DiNAQOR, Sudha Babu, Regulatory CMC Leader, Spark Therapeutics and More
 

Informazioni ed Iscrizioni:

https://go.evvnt.com/1439816-2?pid=4832
Ms. Emily Birt
 
Categorie
Sanità Pubblica (Public Health), Servizi sanitari
Lingua
Inglese
Quote del Congresso
USD 2999.00 - USD 7095.00
I partecipanti attesi
1000
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."

newTreeOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation Österreichisches Rotes KreuzEuropean Health Forum GasteinHelix - Forschung & Beratung WienAnästhesie in Entwicklungsländern e. V.European Public Health Association (EUPHA)Centro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio Sanitario